1. Home
  2. TLS vs BCYC Comparison

TLS vs BCYC Comparison

Compare TLS & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telos Corporation

TLS

Telos Corporation

HOLD

Current Price

$5.21

Market Cap

391.6M

Sector

Technology

ML Signal

HOLD

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

HOLD

Current Price

$5.70

Market Cap

456.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLS
BCYC
Founded
1969
2009
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
391.6M
456.4M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
TLS
BCYC
Price
$5.21
$5.70
Analyst Decision
Buy
Buy
Analyst Count
5
10
Target Price
$7.75
$19.10
AVG Volume (30 Days)
720.9K
260.5K
Earning Date
03-09-2026
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$144,400,000.00
$28,339,000.00
Revenue This Year
$52.26
N/A
Revenue Next Year
$19.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.44
N/A
52 Week Low
$1.83
$5.85
52 Week High
$8.36
$13.47

Technical Indicators

Market Signals
Indicator
TLS
BCYC
Relative Strength Index (RSI) 42.83 32.29
Support Level $5.42 $6.22
Resistance Level $5.75 $6.61
Average True Range (ATR) 0.26 0.36
MACD -0.02 -0.09
Stochastic Oscillator 13.85 10.03

Price Performance

Historical Comparison
TLS
BCYC

About TLS Telos Corporation

Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Share on Social Networks: